Comparing Clinical Outcomes of Steroid-Sparing Therapy With Rituximab Versus Rituximab Alone in Pemphigus

CONCLUSIONS: The use of SST with rituximab dosing did not improve clinical outcomes related to time to remission, reduction in prednisone dosing, or relapse. These data provide further evidence for the use of rituximab in the majority of pemphigus patients without the need for SST. J Drugs Dermatol. 2024;23(3):e97-e99    doi:10.36849/JDD.7949e.PMID:38443121 | DOI:10.36849/jdd.7949

Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Danielle E Mustin Emily F Cole Rebecca Leibowitz Ron J Feldman Source Type: research